Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Controversies in Acne and Rosacea
Description
The session on acne and rosacea controversies discussed several key topics, beginning with concerns over benzene contamination in benzoyl peroxide products. John Barbieri, a dermatologist and epidemiologist, emphasized that while the FDA petition raised important questions about potential benzene levels in benzoyl peroxide, the lack of comprehensive data on baseline levels hindered conclusive safety assessments. He advocated for transparency from testing companies and suggested that benzoyl peroxide could still be used safely if proper storage conditions were observed. Moving on to isotretinoin, he presented evidence from meta-analyses indicating that it may improve mood rather than worsen it, advocating careful monitoring of patients but not shying away from this treatment for patients with a history of depression. The discussion also covered the efficacy of different topical retinoids and antibiotics in acne management. Adapalene and topical benzoyl peroxide were highlighted as effective treatments, while encapsulated benzoyl peroxide showed promise for rosacea. Additionally, the panel noted that relationships between certain treatments, like spironolactone and contraceptives, posed lower risks than previously thought. Overall, the session emphasized evidence-based practices and the necessity for ongoing research and transparency to ensure patient safety and effective treatment choices in dermatology.
View moreConclusions
- Valisure's testing has revealed that benzoyl peroxide products can degrade to produce benzene, a known carcinogen, particularly when subjected to high temperatures.
- There is a need for more transparency from Valisure regarding baseline benzene levels in benzoyl peroxide products and their stability under normal storage conditions.
- Although benzoyl peroxide is associated with potential risks, the current evidence suggests we need to be cautious and not overreact prematurely to these findings.
- Benzoyl peroxide should be stored at room temperature or cooler and not kept for long periods to minimize risks.
- There is a potential for developing more stable formulations of benzoyl peroxide through the use of antioxidants and alternative vehicle solvents.
- Isotretinoin has been found to improve depressive symptoms and reduce suicide risk in the overall population, indicating that it may be safe for use in patients with a history of mental health issues related to acne.
- Individual patients may experience mood changes while on isotretinoin, warranting monitoring and counseling during treatment.
- Routine lab monitoring (CBC, lipids, LFTs) during isotretinoin therapy may not be necessary for generally healthy patients, as clinically significant abnormalities are rare and not likely preventable.
- Adapalene, especially in combination with benzoyl peroxide, is often a good first-line topical treatment for acne due to its efficacy and tolerability.
- Oral isotretinoin remains the most effective systemic treatment for acne, followed by triple therapy using topical retinoids combined with antibiotics and benzoyl peroxide.
- Long-Term Exposure to Low-Level Ambient Benzene and Mortality in a National English Cohort. Am J Respir Crit Care Med. 2023 Dec 21. doi: 10.1164/rccm.202308-1440OC. Online ahead of print.
- Huang et al. J Am Acad Dermatol. 2017 Jun;76(6):1068-1076.e9. doi: 10.1016/j.jaad.2016.12.028. Epub 2017 Mar 11.
- Tan et al. JAMA Dermatol. 2024 Jan 1;160(1):54-62. doi: 10.1001/jamadermatol.2023.4579.
- Bremner et al. J Clin Psychiatry. 2012 Jan;73(1):37-50. doi: 10.4088/JCP.10r05993. Epub 2011 Aug 23.
- Wysowski et al. J Am Acad Dermatol. 2001 Oct;45(4):515-9. doi: 10.1067/mjd.2001.117730.
- Affleck A, Jackson D, Williams HC, Chavez P, Albrecht J. Is routine laboratory testing in healthy young patients taking isotretinoin necessary: a critically appraised topic. Br J Dermatol. 2022 Aug 20.
- Miller J, Ly S, Mostaghimi A, Barbieri JS. JAMA Dermatol. 2021 Apr 7.
- B. Stuart X, E. Maund, C. Wilcox, K. Sridharan, G. Sivaramakrishnan, C. Regas, D. New K.F. Tang, A.Y. Finlay, H.C. Bucher, P. Little, A.M. Layton, M. Santer. Topical preparations for the treatment of mild to moderate acne vulgaris: systematic review and network meta-analysis. 07 April 2021. https://doi.org/10.1111/bjd.20080
- Krunic A, Ciurea A, Scheman A. J Am Acad Dermatol. 2008;58(1):60-62.
- Barbieri JS, Margolis DJ, Mostaghimi A. Temporal Trends and Clinician Variability in Potassium Monitoring of Healthy Young Women Treated for Acne With Spironolactone. JAMA Dermatol. 2021;157(3):296-300.